Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Chae, Hyojin ^a,b   Kim, Myungshin ^a,b   Koh, Yoon Seok ^c   Hwang, Byung Hee ^d   Kang, Min Kyu ^d   Kim, Yonggoo ^a,b   Park, Hae Il ^a,b   Chang, Kiyuk ^d  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Uijeongbu St Mary's Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ADD ON THERAPY; AGED; ARTICLE; DNA POLYMORPHISM; DRUG METABOLISM; FEASIBILITY STUDY; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HUMAN; KOREA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PATIENT CODING; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PLATELET REACTIVITY; POINT OF CARE TESTING; THROMBOCYTE FUNCTION; ALLELE; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; HOSPITAL INFORMATION SYSTEM; PATHOLOGY; PERSONALIZED MEDICINE; THROMBOCYTE; THROMBOCYTE COUNT;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MICROARRAY ANALYSIS; PLATELET COUNT; POINT-OF-CARE SYSTEMS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 84876545410     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/154073     Document Type: Article

References (15)

1. Müller I., Besta F., Schulz C., Massberg S., Schönig A., Gawaz M., Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thrombosis and Haemostasis 2003 89 5 783 787 2-s2.0-0038291914 (Pubitemid 36603418)
2. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Seminars in Thrombosis and Hemostasis 2005 31 2 174 183 2-s2.0-18044378766 10.1055/s-2005-869523 (Pubitemid 40605192)
3. Buchan B. W., Peterson J. F., Cogbill C. H., Evaluation of a microarray-based genotyping assay for the rapid detection of cytochrome P450 2C19 *2 and *3 polymorphisms from whole blood using nanoparticle probes. American Journal of Clinical Pathology 2011 136 4 604 608
4. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C. W., Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thrombosis and Haemostasis 2009 101 2 333 339 2-s2.0-62449095155 10.1160/TH08-09-0577
5. Bonello L., Tantry U. S., Marcucci R., Blindt R., Angiolillo D. J., Becker R., Bhatt D. L., Cattaneo M., Collet J. P., Cuisset T., Gachet C., Montalescot G., Jennings L. K., Kereiakes D., Sibbing D., Trenk D., Van Werkum J. W., Paganelli F., Price M. J., Waksman R., Gurbel P. A., Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. Journal of the American College of Cardiology 2010 56 12 919 933 2-s2.0-77953911457 10.1016/j.jacc.2010.04.047
6. Chen L., Qin S., Xie J., Tang J., Yang L., Shen W., Zhao X., Du J., He G., Feng G., He L., Xing Q., Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 2008 9 6 691 702 2-s2.0-48949119312 10.2217/14622416.9.6.691
7. Gladding P., White H., Voss J., Ormiston J., Stewart J., Ruygrok P., Bvaldivia B., Baak R., White C., Webster M., Pharmacogenetic testing for clopidogrel using the rapid infiniti analyzer. A Dose-Escalation Study. Cardiovascular Interventions 2009 2 11 1095 1101 2-s2.0-70449509294 10.1016/j.jcin.2009.08.018
8. Lee C. C., McMillin G. A., Babic N., Melis R., Yeo K. T. J., Evaluation of a CYP2C19 genotype panel on the GenMark eSensor platform and the comparison to the Autogenomics Infiniti ™ and Luminex CYP2C19 panels. Clinica Chimica Acta 2011 412 11-12 1133 1137 2-s2.0-79955014308 10.1016/j.cca.2011.03.001
9. Roberts J. D., Wells G. A., Le May M. R., Point-of-care genetic testing for personalisation of antiplatelet treatmetn (RAPID GENE): a prospective, randomised, proof-of-concept trial. The Lancet 2012 379 9827 1705 1722
10. Langley M. R., Booker J. K., Evans J. P., McLeod H. L., Weck K. E., Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. Journal of Molecular Diagnostics 2009 11 3 216 225 2-s2.0-67149091240 10.2353/jmoldx.2009. 080123
11. Nguyen T. A., Diodati J. G., Pharand C., Resistance to clopidogrel: a review of the evidence. Journal of the American College of Cardiology 2005 45 8 1157 1164 2-s2.0-17144370263 10.1016/j.jacc.2005.01.034 (Pubitemid 40523131)
12. Qin X. P., Xie H. G., Wang W., Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clinical Pharmacology and Therapeutics 1999 66 6 642 646 (Pubitemid 30014093)
13. Jeong Y. H., Tantry U. S., Kim I. S., Effect of CYP2C19 *2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circulation Cardiovascular Interventions 2011 4 6 585 594
14. Man M., Farmen M., Dumaual C., Teng C. H., Moser B., Irie S., Noh G. J., Njau R., Close S., Wise S., Hockett R., Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. Journal of Clinical Pharmacology 2010 50 8 929 940 2-s2.0-77955082077 10.1177/0091270009355161
15. Storhoff J. J., Marla S. S., Bao P., Hagenow S., Mehta H., Lucas A., Garimella V., Patno T., Buckingham W., Cork W., Müller U. R., Gold nanoparticle-based detection of genomic DNA targets on microarrays using a novel optical detection system. Biosensors and Bioelectronics 2004 19 8 875 883 2-s2.0-10744230667 10.1016/j.bios.2003.08.014 (Pubitemid 38201338)